Rigel Pharmaceuticals (Rigel Pharmaceuticals) Total Liabilities : $145.9 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Rigel Pharmaceuticals Total Liabilities?

Rigel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was $145.9 Mil.

Rigel Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2023 ($145.21 Mil) to Sep. 2023 ($147.16 Mil) but then declined from Sep. 2023 ($147.16 Mil) to Dec. 2023 ($145.87 Mil).

Rigel Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($136.95 Mil) to Dec. 2022 ($147.90 Mil) but then declined from Dec. 2022 ($147.90 Mil) to Dec. 2023 ($145.87 Mil).

Rigel Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Rigel Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Total Liabilities Chart

Rigel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

93.75

76.35

136.95

147.90

145.87

Rigel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															147.90	147.87	145.21	147.16	145.87

Rigel Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Rigel Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	53.267	+	(52.658	+	39.944
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	145.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	117.225	-	-28.644
	=	145.9

Rigel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	53.267	+	(52.658	+	39.944
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	145.9

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	117.225	-	-28.644
	=	145.9

Rigel Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RI2A:Germany

Address

611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080

Website

https://www.rigel.com

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Executives

Raul R Rodriguez	officer: Sr VP of Bus Dev and Com Ops	1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos	officer: EVP, Chief Commercial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer	officer: EVP & CMO	5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno	officer: EVP & Chief Financial Officer	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey	officer: EVP, GC & Corp Sec	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah	director	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin	director	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan	officer: Principal Accounting Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege	officer: Chief Medical Officer	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii	officer: EVP & Chief Commercial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel	officer: EVP Human Resources	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080